SCHEMBL26985082

SCHEMBL26985082

Nc1nccc(Cc2cncc(Nc3ccc(Cl)cc3F)c2C(F)(F)F)c1F

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ NUDT1 P36639 3/20 0.39
▸ KDR P35968 9/20 0.36
▸ FLT1 P17948 5/20 0.36
▸ EGFR P00533 3/20 0.36
▸ PDGFRB P09619 1/20 0.36
▸ FGFR1 P11362 2/20 0.34
▸ TRPM5 Q9NZQ8 1/20 0.32
▸ CNR2 P34972 1/20 0.32
▸ ATR Q13535 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ MAP2K1 Q02750 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.30
▸ NPC1 O15118 1/20 0.30
▸ ALOX15 P16050 1/20 0.30
▸ TSHR P16473 1/20 0.30
▸ RAB9A P51151 1/20 0.30
▸ SMN1; SMN2 Q16637 1/20 0.30
▸ HSD17B10 Q99714 1/20 0.30
▸ CSF1R P07333 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30746627 1.00 NUDT1 (0.39) NUDT1KDRFLT1EGFRPDGFRB
SCHEMBL26985138 0.89 NUDT1 (0.42) NUDT1KDRFLT1EGFRPDGFRB
SCHEMBL30746708 0.89 NUDT1 (0.42) NUDT1KDRFLT1EGFRPDGFRB
SCHEMBL26984929 0.88 NUDT1 (0.41) NUDT1KDRFLT1EGFRPDGFRB
SCHEMBL30746421 0.88 NUDT1 (0.41) NUDT1KDRFLT1EGFRPDGFRB
SCHEMBL26984868 0.86 NUDT1 (0.42) NUDT1KDRFLT1EGFRPDGFRB
SCHEMBL26984869 0.83 KDR (0.41) NUDT1KDRFLT1EGFRPDGFRB
SCHEMBL30746466 0.83 KDR (0.41) NUDT1KDRFLT1EGFRPDGFRB
SCHEMBL30746525 0.82 NUDT1 (0.38) NUDT1KDRFLT1EGFRPDGFRB
SCHEMBL26985377 0.82 NUDT1 (0.38) NUDT1KDRFLT1EGFRPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001845-A1 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS INC (US) 2026-01-01 — — US disclosed
US-20250288571-A1 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS, INC. 2025-09-18 — — US disclosed
CN-120129678-A Mitogen-activated protein kinase (MEK) inhibitors 耐斯泰德医疗公司 2025-06-10 — — CN disclosed
EP-4551558-A2 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS Nested Therapeutics, Inc. (US) 2025-05-14 — — EP disclosed
WO-2024010925-A2 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS, INC. (US) 2024-01-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260001845-A1 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS MAPK6, MAPK3, MAPK1 NUDT1 1810/4885KDR 818/4885FLT1 3167/4885
US-20250288571-A1 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS BRAF, MAP3K1, MAP3K5 NUDT1 2559/4885KDR 911/4885FLT1 1164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback